Prelude Therapeutics Incorporated
PRLD
$1.21
-$0.03-2.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 4.00M | 3.00M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 4.00M | 3.00M | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 4.00M | 3.00M | -- |
| SG&A Expenses | 6.41M | 5.79M | 6.21M | 7.92M | 7.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.19M | 34.61M | 37.83M | 37.38M | 37.16M |
| Operating Income | -32.19M | -34.61M | -33.83M | -34.38M | -37.16M |
| Income Before Tax | -31.23M | -32.09M | -28.73M | -32.27M | -34.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.23M | -32.09M | -28.73M | -32.27M | -34.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.23M | -32.09M | -28.73M | -32.27M | -34.74M |
| EBIT | -32.19M | -34.61M | -33.83M | -34.38M | -37.16M |
| EBITDA | -31.76M | -34.17M | -33.34M | -33.97M | -36.71M |
| EPS Basic | -0.41 | -0.42 | -0.38 | -0.43 | -0.46 |
| Normalized Basic EPS | -0.26 | -0.26 | -0.24 | -0.27 | -0.29 |
| EPS Diluted | -0.41 | -0.42 | -0.38 | -0.43 | -0.46 |
| Normalized Diluted EPS | -0.26 | -0.26 | -0.24 | -0.27 | -0.29 |
| Average Basic Shares Outstanding | 75.99M | 75.99M | 75.87M | 75.86M | 75.76M |
| Average Diluted Shares Outstanding | 75.99M | 75.99M | 75.87M | 75.86M | 75.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |